tadalafil has been researched along with cifenline in 2 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (cifenline) | Trials (cifenline) | Recent Studies (post-2010) (cifenline) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 303 | 49 | 33 |
| Protein | Taxonomy | tadalafil (IC50) | cifenline (IC50) |
|---|---|---|---|
| Sodium channel protein type 1 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 4 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 7 subunit alpha | Homo sapiens (human) | 7.8 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 8.8 | |
| Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 9 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 2 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 3 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 11 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 8 subunit alpha | Homo sapiens (human) | 7.8 | |
| Sodium channel protein type 10 subunit alpha | Homo sapiens (human) | 7.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faller, B; Trunzer, M; Zimmerlin, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
2 other study(ies) available for tadalafil and cifenline
| Article | Year |
|---|---|
Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.
Topics: Chromatography, Liquid; Drug Design; Humans; Likelihood Functions; Microsomes, Liver; Pharmacokinetics; Tandem Mass Spectrometry | 2009 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |